Published in final edited form as:

Breast Cancer Res Treat. 2018 February ; 168(1): 229–239. doi:10.1007/s10549-017-4582-0.

Comparative Effectiveness of Incorporating a Hypothetical DCIS Prognostic Marker into Breast Cancer Screening

Amy Trentham-Dietz^{1,2}, Mehmet Ali Ergun³, Oguzhan Alagoz^{2,3}, Natasha K. Stout⁴, Ronald E. Gangnon^{1,2,5}, John M. Hampton^{1,2}, Kim Dittus^{6,7}, Ted A. James⁸, Pamela M. Vacek^{7,9}, Sally D. Herschorn^{7,10}, Elizabeth S. Burnside^{2,11}, Anna N. A. Tosteson¹², Donald L. Weaver^{7,13}, and Brian L. Sprague^{7,14}

¹Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA

²University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA

³Department of Industrial and Systems Engineering, University of Wisconsin-Madison, Madison, WI, USA

⁴Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA

⁵Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA

⁶Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA

⁷University of Vermont Cancer Center, Burlington, VT, USA

⁸BreastCare Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

⁹Department of Medical Biostatistics, Larner College of Medicine, University of Vermont, Burlington, VT, USA

¹⁰Department of Radiology, Larner College of Medicine, University of Vermont, Burlington, VT, USA

¹¹Department of Radiology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA

Correspondence to: Amy Trentham-Dietz, PhD, University of Wisconsin-Madison, 610 Walnut St, WARF Room 307, Madison, WI 53726 (trentham@wisc.edu, Tel 608-265-4175); or Brian L. Sprague, PhD, Burlington, VT (brian.sprague@uvm.edu).

Author contributions

The authors are solely responsible for the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication.

Compliance with ethical standards

The University of Wisconsin Health Sciences Human Subjects Committee determined that this study was exempt from review.

Conflicts of interest

Dr. Herschorn reports previously owning stock and currently serving as an unpaid advisor for Hologic. All other authors have no conflicts to disclose.

¹²The Dartmouth Institute for Health Policy and Clinical Practice and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA

¹³Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA

¹⁴Department of Surgery, Larner College of Medicine, University of Vermont, Burlington, VT, USA

Abstract

Purpose—Due to limitations in the ability to identify non-progressive disease, ductal carcinoma in situ (DCIS) is usually managed similarly to localized invasive breast cancer. We used simulation modeling to evaluate the potential impact of a hypothetical test that identifies non-progressive DCIS.

Methods—A discrete-event model simulated a cohort of US women undergoing digital screening mammography. All women diagnosed with DCIS underwent the hypothetical DCIS prognostic test. Women with test results indicating progressive DCIS received standard breast cancer treatment and a decrement to quality of life corresponding to the treatment. If the DCIS test indicated non-progressive DCIS, no treatment was received and women continued routine annual surveillance mammography. A range of test performance characteristics and prevalence of non-progressive disease was simulated. Analysis compared discounted quality-adjusted life years (QALYs) and costs for test scenarios to base-case scenarios without the test.

Results—Compared to the base-case, a perfect prognostic test resulted in a 40% decrease in treatment costs, from \$13,321 to \$8,005 USD per DCIS case. A perfect test produced 0.04 additional QALYs (16 days) for women diagnosed with DCIS, added to the base case of 5.88 QALYs per DCIS case. The results were sensitive to the performance characteristics of the prognostic test, the proportion of DCIS cases that are non-progressive in the model, and the frequency of mammography screening in the population.

Conclusion—A prognostic test that identifies non-progressive DCIS would substantially reduce treatment costs but result in only modest improvements in quality of life when averaged over all DCIS cases.

Keywords

ductal carcinoma in situ; prognosis; breast cancer; indolent disease; quality-adjusted life years; costs

Introduction

Approximately 20% of U.S. women diagnosed with breast cancer have ductal carcinoma in situ (DCIS).[1] This percentage is even greater (over 27%) among women who regularly participate in mammography screening.[2] Approximately 85% of DCIS is diagnosed asymptotically through screening mammography.[3] As of 2016, over 1 million women are estimated to have a personal history of a DCIS diagnosis.[4] Several lines of research suggest that a substantial fraction of DCIS—perhaps more than half—would never have caused the women harm if the DCIS had remained undetected.[5–8] Because a significant

proportion will progress to invasive disease, treatment for DCIS typically is similar to approaches for locally limited invasive breast cancer including excision, radiation, and adjuvant endocrine therapy. Increasingly women are choosing ipsilateral mastectomy, contralateral risk-reduction mastectomy, and breast reconstruction which have substantial impacts relating to quality of life and financial costs.[9]

In 2011, a new multigene assay for estimating the 10-year risk of local recurrence, the Oncotype DX® DCIS Score™, became available for women with DCIS treated by local excision.[10] Although use of the DCIS Score assay is limited due to concerns of patient eligibility and lack of consideration of non-molecular predictive factors such as margin width and nuclear grade,[11] independent studies confirm that this 12-gene assay predicts local recurrence after DCIS [12] and influences decisions regarding radiotherapy after breast conserving surgery.[13] Additional approaches using features to identify the malignant potential of a DCIS lesion are actively under investigation, most often by combining different sources of information regarding histological and molecular markers as well as method of detection.[14–16]

In anticipation of the development of more accurate methods of identifying non-progressive DCIS, we used the University of Wisconsin Breast Cancer Simulation Model to evaluate the impact of a hypothetical prognostic test for DCIS. Simulation modeling is a valuable tool to estimate the population impact of a new or hypothetical intervention as it allows for using multiple sources of input data without risk to human subjects. We started by assuming a perfect prognostic test to estimate, under ideal circumstances, the maximum impact on costs and quality of life if non-progressive DCIS lesions were not treated beyond diagnostic biopsy, sparing women further treatment. We then explored the impact of alternative assumptions of test performance, DCIS tumor growth, and screening mammography utilization.

Methods

University of Wisconsin Breast Cancer Simulation Model

The University of Wisconsin Breast Cancer Simulation Model is a discrete-event simulation model that uses multiple sources of U.S. cancer data to generate registry-like datasets of breast cancer incidence and mortality statistics according to patient demographics.[17] The model was developed as part of the Cancer Intervention and Surveillance Modeling Network (CISNET), a consortium funded by the National Cancer Institute.[18, 19] The simulation model is used to consider the benefits and harms of alternate screening and treatment programs for breast cancer.[20–24] The University of Wisconsin Health Sciences Human Subjects Committee determined that this study was exempt from review.

Briefly, the simulation model has four main components – natural history, detection, treatment, and non-breast cancer mortality;[25] additional information regarding the model is included in Figure 1 and Appendix Table 1.[18, 23, 26–39] The natural history component assumes that the probability of breast cancer onset is a function of risk based on trends in breast cancer according to single years of age at diagnosis, years of diagnosis, and years of birth.[26, 27] In the model, all invasive breast cancer tumors first progress through DCIS, so

that a “tumor” can be either invasive or DCIS. Tumor growth is a function of a random initial growth parameter, with a fraction of tumors (initially set through calibration) having limited malignant potential, i.e. non-progressive growth. Thus, in the primary analysis, we did not assume *a priori* a specific fraction of non-progressive disease; rather the fraction of non-progressive disease (30-50% with a “best” estimate of 42%) was determined by testing different fractions for the best fit to observed historical patterns in stage-specific breast cancer incidence. In other words, not all DCIS or small localized invasive cancers progress to become a lethal event. After reaching a maximum size, also set through calibration, non-progressive tumors stop growing. If undetected, all non-progressive tumors become undetectable or disappear from the model after reaching their maximum size for a specified time set through calibration (2 years).

The detection component assumes that breast cancer can either be detected by screening mammography or through clinical surfacing by clinical examination or self-detection.[27] The probability that any undetected tumor will be symptomatically detected is a function of tumor diameter, so that larger tumors are more likely to be clinically detected at any time relative to smaller tumors. Screen detection of a tumor during the preclinical detectable period could result in the identification and treatment of earlier stage or smaller tumors and lead to breast cancer mortality reduction. Sensitivity of digital mammography depends on a woman’s age (<50, 50-69, and 70), breast density, and also on tumor diameter and calendar year.[25] In addition, the probability that a woman has a digital mammogram is a function of calendar year and age, so that it is more likely that a woman will have a mammogram with increasing age and time.[30] Screening mammography rates are based on observed dissemination patterns in the U.S. estimated from the Breast Cancer Surveillance Consortium.[30, 40]

Breast cancer treatment is modeled using a “cured”/“not cured” approach. Uncured tumors continue to grow until they reach the distant disease stage and, eventually, cause death from breast cancer unless the woman dies from other causes or reaches age 100 (the end of the simulation). The probability of cure depends on the treatment given, tumor stage at detection, and age.[25] Surgical treatment assignment depends on the year when the tumor was detected based on patterns of care observed in the SEER Program and the National Cancer Data Base;[9, 23] adjuvant therapy is assigned based on stage of disease at detection and ER/HER2 status.[41] Survival rates for specific treatments including surgery, radiation, chemotherapy, endocrine therapy, and targeted therapy (e.g., trastuzumab) are based on recent clinical trial results.[23, 32] The non-breast cancer mortality component assumes that death from other causes will occur independently of a woman’s breast cancer status, and the probability of death from other causes depends on age.[38, 42]

The simulated population included women born in 1970. This birth cohort was chosen since these women experience modern conditions (e.g., digital mammography performance, treatment effectiveness, competing mortality, etc.) and for consistency with recent collaborative modeling reports.[18, 22] Current digital mammography performance and treatment effectiveness were used for future calendar years. In each simulation, subgroups of women were followed from age 20 until death or age 100, whichever occurs first.

Outcomes

In all simulated scenarios, primary outcomes were quality-adjusted life years (QALYs) and costs. We used age-specific quality of life weights for general health based on utilities from noninstitutionalized female civilians in the US (Appendix Table 1).[33] Adjustments were made for stage-specific breast cancer treatment. Costs were divided into annual surveillance mammography costs among diagnosed DCIS cases who were not treated beyond biopsy, stage-specific treatment costs (including subsequent surveillance mammography among treated cases),[19, 36] and prognostic test costs, reported in 2015 U.S. dollars (Table 1). Cost of the hypothetical DCIS prognostic test was assumed to be \$3,419.42, based on Medicare reimbursement for a currently available diagnostic test (Oncotype DX® Breast DCIS Score™, HCPSC 81519). Life years, QALYs, and costs were discounted at 3% per year.

Secondary outcomes included breast cancer deaths, life-years, the numbers of prognostic tests, and the number of DCIS cases treated (or not treated).

Comparison Scenario: Current Practice for DCIS Management

As our primary comparison scenario, we assumed current mammography dissemination and modern breast cancer treatment. The hypothetical DCIS prognostic test was not implemented. All women diagnosed with breast cancer were given treatment (100% adherence) according to guidelines.

Alternate Scenarios: DCIS Prognostic Test

One primary alternate scenario was modeled by modifying the simulation model to include application of a perfect DCIS prognostic test at the time of diagnosis (Figure 1, panel B). If the test was “positive”, indicating non-progressive disease, then the case was not treated beyond diagnostic biopsy, thus also avoiding a decrement to quality of life associated with treatment. DCIS cases with positive prognostic tests were assigned annual mammography (“surveillance” mammography after diagnosis) until death or a diagnosis with invasive breast cancer. (Under this scenario with the perfect test, no “non-progressive” DCIS progressed to invasive breast cancer; this only occurred with false-positive prognostic tests in the sensitivity analysis, described below.) If the prognostic test was “negative”, indicating that the tumor was progressive, then the case received standard treatment.

Analysis

Two million women were simulated for each scenario. Outcomes were compared between the scenarios with and without a perfect hypothetical DCIS prognostic test (100% sensitivity, 100% specificity). We compared additional scenarios to examine the effects of variation in prognostic test performance characteristics, quality of life decrements, and model parameters governing disease progression. Prognostic test performance was varied such that sensitivity of the prognostic test to identify non-progressive disease ranged 50-95% while specificity of the test to identify progressive disease ranged 70-95%. We varied decrements in quality of life associated with breast cancer treatment; specifically, we increased the disutility of treatment for DCIS and localized invasive breast cancer (from 0.1 to 0.2) since stage-specific treatment disutilities were initially small for early-staged disease (Table 1). [19, 35] We varied model parameters regarding non-progressive tumors by setting

the percent of DCIS tumors designated as non-progressive as 30% or 50%, instead of the “best” value set through calibration (42%), to reflect the range generally reported in the literature. Finally, we examined alternative schedules for screening mammography (for women without a personal history of breast cancer) including those recommended by the U.S. Preventive Services Task Force (biennial ages 50-74 y), the American Cancer Society (annual 45-54 y, biennial 55-79 y), and the American College of Radiology (annual 40-74 y).

Results

In the absence of a DCIS prognostic test, the model predicted that 13.9% of women were diagnosed with breast cancer in their lifetimes. Slightly over 20% of breast cancers were DCIS (20.6%); overall, 8% of all breast cancer cases and 3% of DCIS cases died of breast cancer. Costs were estimated to equal \$13,321 per DCIS case.

In the perfect test scenario, the DCIS prognostic test was applied to 2.8% of all women (2,844 per 100,000), with approximately 60% of tests positive for a non-progressive lesion (1,696 per 100,000) (Table 2). Although 42% of all breast cancer tumors were non-progressive at onset, the percent of non-progressive tumors decreases with increasing stage at diagnosis. Thus, 60% of DCIS cases were spared treatment. Among women diagnosed with DCIS, the gain in QALYs was modest (0.044 per case, or 16 days of perfect health) and mortality was unchanged (3.0%), however, the reduction in costs was substantial. All DCIS cases experienced the cost of the prognostic test with an estimated total expected discounted cost per DCIS case of \$1,598 (assuming a 3% annual discounting factor for future costs). DCIS cases with positive prognostic tests incurred surveillance mammography costs (\$705 per case), whereas DCIS cases with negative tests incurred both surveillance mammography and treatment costs. Total lifetime costs were reduced by 40% averaged across all DCIS cases.

In scenarios where specificity remained perfect (no progressive disease was misidentified as non-progressive) but sensitivity was decreased as low as 20% (as little as 20% of non-progressive disease tested positive), breast cancer mortality among cases diagnosed with DCIS remained unchanged and the effect on QALYs was small, but costs increased from \$8,334 to \$13,521 per DCIS case (Table 3). In scenarios with perfect sensitivity but reduced specificity (some progressive disease was misidentified as non-progressive), the effect on QALYs and costs was modest and breast cancer deaths among women diagnosed with DCIS increased by 0.1-0.4% (2 to 11 per 100,000 women). Changes in sensitivity had a greater effect on the number of DCIS cases that avoided treatment than changes in specificity (Figure 2).

Changing the decrement in quality of life associated with DCIS and localized invasive treatment from 0.1 to 0.2 for 2 years doubled the gain in QALYs for DCIS cases in the presence of a perfect test from 16 to 32 days (Table 2). When we varied assumptions by increasing the prevalence of non-progressive breast tumors, the benefits of a DCIS prognostic test were greater, with a savings of almost \$1000 per DCIS case if 50% were non-progressive instead of 42%.

Varying screening schedules did not substantially impact outcomes (Appendix Table 2). Screening strategies with more frequent mammography generally lead to greater numbers of detected DCIS with slightly fewer cases avoiding treatment and slightly greater costs in the presence of a DCIS prognostic test, but these differences were small.

Discussion

This modeling study demonstrates the maximum potential impact of a hypothetical prognostic test for non-progressive DCIS. Results showed that, under optimal conditions, treatment cost savings would be substantial in the presence of an accurate prognostic test. Given about 63,000 women are diagnosed with DCIS in the U.S. each year,[43] this corresponds to an annual savings of over \$334 million. The availability of a perfect DCIS prognostic test would improve quality of life, on average, about 2 to 4 weeks of perfect health across all women diagnosed with DCIS. The estimated utility of the perfect prognostic (0.044) is slightly greater than the quality of life impact of a screening mammogram (0.01 to 0.03) but smaller than the impact of breast conserving surgery (0.07 to 0.09).[44–46]

Our primary analysis assumed that the hypothetical prognostic test was perfectly accurate. While this assumption is unrealistic, these results demonstrate the optimal impact of a prognostic test that can be anticipated. Our scenario analyses demonstrate how the projected costs and the number of DCIS cases that avoided treatment are dependent on test sensitivity; conversely, breast cancer mortality depends on test specificity. The cost of the prognostic test was based on current Medicare reimbursement for the Oncotype DX test which is greater than the costs of surveillance mammography or breast MRI but less than the costs of breast cancer treatment. We estimated costs of surveillance mammography in women with a positive diagnostic test, but it is likely that a variety of surveillance approaches would be utilized in the setting of a prognostic test (e.g., imaging with MRI or more frequent mammography), so that our analysis did not fully estimate the variety or magnitude of surveillance costs.

The breast cancer simulation model has been calibrated to match breast cancer incidence and mortality as observed in the U.S., and incorporates inputs on modern screening performance and treatment benefit. Other model inputs are unobservable or difficult to quantify, so that the model requires certain assumptions. We explored the extent that assumptions regarding tumor growth, quality of life utilities, and the frequency of mammography screening had on the results. In particular, the percent of tumors designated at biological onset as non-progressive (42%) was initially set through model calibration.[17] We conducted a series of secondary analyses to explore the impact of this parameter and found that results were sensitive to the fraction of tumors that were non-progressive; the value of a prognostic test increases along with the fraction of tumors that are non-progressive. The proportion of DCIS lesions that are non-progressive is debated, with studies finding a very wide range of potential values, from 10 to 80%.[5–8] We also assumed that positive results of the hypothetical prognostic test meant that women avoided all treatment including excision, whereas potentially more likely clinical scenarios for such a test may include breast conserving surgery or endocrine therapy and avoidance of some but not all treatment

approaches. Thus the costs savings resulting from our modeling experiments describe the most optimistic scenario in terms of cost savings. Treatment costs used in this study arise from studies that provided values for the phase of care (initial, interim, end of life) rather than for the type of treatment (surgery, radiation, endocrine therapy),[36] thus preventing estimation of cost savings when specific treatments are omitted. Our model was also limited since women were at risk of only a single breast cancer diagnosis; future studies should consider risk of multiple primaries since over 10% of breast cancer survivors experience a second primary diagnosis.[47] In addition, future analysis should account for up-staging that occurs among approximately 24% of women who are diagnosed with DCIS at biopsy but have invasive breast cancer detected at the time of surgery.[48] Finally, we did not estimate emotional costs such as anxiety that might be associated with DCIS testing and forgoing treatment. Randomized trials investigating these issues will shed light on these qualitative components of the clinical cascade, which will then be available for modeling in the future.

Efforts to identify indolent DCIS and improve decision-making surrounding treatment for early-stage breast cancer are ongoing, and recent developments in molecular-based assays will likely play an important role in future DCIS management. Alternative approaches to immediate surgery, including active surveillance using advanced imaging, are also under evaluation.[49] While randomized trials will ultimately provide evidence regarding the benefits of actual prognostic tests in the future, simulation modeling is a valuable tool to explore unobservable phenomenon like tumor growth in asymptomatic women. Modeling also allows incorporation of multiple data sources to inform the analysis based on modern breast cancer screening and treatment. This study provides estimates of the potential impact of implementing a tailored approach to DCIS therapy, where women with greater risk of recurrence or a second breast cancer diagnosis receive more extensive treatment. Our findings suggest that a DCIS prognostic test that could identify non-progressive DCIS would substantially reduce costs associated with DCIS management.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Berta Geller, Julie McGregor, Kathy Peck, Oyewale Shiyabola, Dawn Pelkey, and Kathleen Howe for their advice, project management, and assistance with data for this project.

Funding

This work was supported by the National Cancer Institute at the National Institutes of Health for the Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) Program (grant number U54 CA163303) and other projects (grant numbers U01 CA199218, P30 CA014520 and U54CA163307). Data collection for model inputs from the Breast Cancer Surveillance Consortium (BCSC) was supported by the National Cancer Institute Grant P01 CA154292, contract HSN261201100031C and Grant U54 CA163303. The collection of BCSC cancer and vital status data used in this study was supported in part by several state public health departments and cancer registries throughout the US. For a full description of these sources, please see: <http://breastscreening.cancer.gov/work/acknowledgement.html>.

References

1. Howlader, N., Noone, AM., Krapcho, M., Miller, D., Bishop, K., Altekruse, SF., Kosary, CL., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, DR., Chen, HS., Feuer, EJ., Cronin, KA. SEER Cancer Statistics Review, 1975–2013. National Cancer Institute; Bethesda, MD: http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016
2. Miglioretti DL, Zhu W, Kerlikowske K, Sprague BL, Onega T, Buist DS, Henderson LM, Smith RA, Breast Cancer Surveillance C. Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status. *JAMA oncology*. 2015; 1:1069–1077. DOI: 10.1001/jamaoncol.2015.3084 [PubMed: 26501844]
3. Sprague BL, McLaughlin V, Hampton JM, Newcomb PA, Trentham-Dietz A. Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study. *Breast Cancer Res Treat*. 2013; 141:145–154. DOI: 10.1007/s10549-013-2670-3 [PubMed: 23979007]
4. Sprague BL, Trentham-Dietz A. Prevalence of breast carcinoma in situ in the United States. *JAMA*. 2009; 302:846–848. [PubMed: 19706857]
5. Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ. Characterizing the impact of 25 years of DCIS treatment. *Breast Cancer Res Treat*. 2011; 129:165–173. DOI: 10.1007/s10549-011-1430-5 [PubMed: 21390494]
6. Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW. Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. *Eur J Cancer*. 2003; 39:1746–1754. [PubMed: 12888370]
7. Independent U. K. Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. *Lancet*. 2012; 380:1778–1786. DOI: 10.1016/S0140-6736(12)61611-0 [PubMed: 23117178]
8. Etzioni R, Gulati R, Mallinger L, Mandelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. *Ann Intern Med*. 2013; 158:831–838. DOI: 10.7326/0003-4819-158-11-201306040-00008 [PubMed: 23732716]
9. Shiyanbola OO, Sprague BL, Hampton JM, Dittus K, James TA, Herschorn S, Gangnon RE, Weaver DL, Trentham-Dietz A. Emerging trends in surgical and adjuvant radiation therapies among women diagnosed with ductal carcinoma in situ. *Cancer*. 2016; 122:2810–2818. DOI: 10.1002/cncr.30105 [PubMed: 27244699]
10. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. *J Natl Cancer Inst*. 2013; 105:701–710. DOI: 10.1093/jnci/djt067 [PubMed: 23641039]
11. Lagios MD, Silverstein MJ. Risk of recurrence of ductal carcinoma in situ by oncotype Dx technology: some concerns. *Cancer*. 2014; 120:1085. doi: 10.1002/cncr.28523 [PubMed: 24382657]
12. Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, Tuck A, Sengupta S, Elavathil L, Jani PA, Bonin M, Chang MC, Robertson SJ, Slodkowska E, Fong C, Anderson JM, Jamshidian F, Miller DP, Cherbavaz DB, Shak S, Paszat L. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. *Breast Cancer Res Treat*. 2015; 152:389–398. DOI: 10.1007/s10549-015-3464-6 [PubMed: 26119102]
13. Alvarado M, Carter DL, Guenther JM, Hagans J, Lei RY, Leonard CE, Manders J, Sing AP, Broder MS, Cherepanov D, Chang E, Eagan M, Hsiao W, Schultz MJ. The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score result. *J Surg Oncol*. 2015; 111:935–940. DOI: 10.1002/jso.23933 [PubMed: 26031501]
14. Molinaro AM, Sison JD, Ljung BM, Tlsty TD, Kerlikowske K. Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy. *Breast Cancer Res Treat*. 2016; 157:351–361. DOI: 10.1007/s10549-016-3814-z [PubMed: 27146587]

15. Benson JR, Wishart GC. Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery. *Lancet Oncol.* 2013; 14:e348–357. DOI: 10.1016/S1470-2045(13)70135-9 [PubMed: 23896274]
16. Yi M, Meric-Bernstam F, Kuerer HM, Mittendorf EA, Bedrosian I, Lucci A, Hwang RF, Crow JR, Luo S, Hunt KK. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. *J Clin Oncol.* 2012; 30:600–607. DOI: 10.1200/JCO.2011.36.4976 [PubMed: 22253459]
17. Alagoz O, Ergun MA, Cevik M, Sprague BL, Fryback DG, Gangnon RE, Hampton JM, Stout NK, Trentham-Dietz A. The University of Wisconsin Breast Cancer Epidemiology Simulation Model: An Update. *Medical Decision Making.* (in press).
18. Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, van den Broek JJ, Alagoz O, Sprague BL, van Ravesteyn NT, Near AM, Gangnon RE, Hampton JM, Chandler Y, de Koning HJ, Mandelblatt JS, Tosteson AN, Breast Cancer Surveillance Consortium, the Cancer Intervention Surveillance Modeling Network. Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes. *Ann Intern Med.* 2016; 165:700–712. DOI: 10.7326/M16-0476 [PubMed: 27548583]
19. Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, Hubbard RA, Miglioretti DL, Munsell MF, Trentham-Dietz A, van Ravesteyn NT, Tosteson AN, Mandelblatt JS. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. *J Natl Cancer Inst.* 2014; 106:dju092.doi: 10.1093/jnci/dju092 [PubMed: 24872543]
20. Lee CI, Cevik M, Alagoz O, Sprague BL, Tosteson AN, Miglioretti DL, Kerlikowske K, Stout NK, Jarvik JG, Ramsey SD, Lehman CD. Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts. *Radiology.* 2015; 274:772–780. DOI: 10.1148/radiol.14141237 [PubMed: 25350548]
21. Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ, Miglioretti DL, Mandelblatt JS, de Koning HJ, Kerlikowske K, Lehman CD, Tosteson AN. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. *Ann Intern Med.* 2015; 162:157–166. DOI: 10.7326/M14-0692 [PubMed: 25486550]
22. Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. *Ann Intern Med.* 2016; 164:215–225. DOI: 10.7326/M15-1536 [PubMed: 26756606]
23. Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. *J Natl Cancer Inst.* 2014; 106 pii: dju289. doi: 10.1093/jnci/dju289
24. Batina NG, Trentham-Dietz A, Gangnon RE, Sprague BL, Rosenberg MA, Stout NK, Fryback DG, Alagoz O. Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis. *Breast Cancer Res Treat.* 2013; 138:519–528. DOI: 10.1007/s10549-013-2435-z [PubMed: 23417335]
25. Mandelblatt, J., Cronin, KA., De Koning, H., Miglioretti, DL., Schechter, C., Stout, N., Breast Working Group of the Cancer Intervention and Surveillance Modeling Network (CISNET) and the Breast Cancer Surveillance Consortium (BCSC). Agency for Healthcare Research and Quality. U.S. Department of Health and Human Services; Rockville, MD: Collaborative Modeling of U.S. Breast Cancer Screening Strategies. (AHRQ Publication No. 14-05201-EF-4, December 2015. Available from: <http://www.uspreventiveservicestaskforce.org/Home/GetFile/1/16255/collabmodelingbc/pdf>. Accessed May 2016)

26. Gangnon RE, Sprague BL, Stout NK, Alagoz O, Weedon-Fekjaer H, Holford TR, Trentham-Dietz A. The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model. *Cancer Epidemiol Biomarkers Prev.* 2015; 24:905–912. DOI: 10.1158/1055-9965.EPI-14-1286 [PubMed: 25787716]
27. Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V, Remington PL. The Wisconsin Breast Cancer Epidemiology Simulation Model. *J Natl Cancer Inst Monogr.* 2006:37–47. [PubMed: 17032893]
28. Schwartz M. A mathematical model used to analyze breast cancer screening strategies. *Oper Res.* 1978; 26:937–955.
29. Shwartz M. Validation and use of a mathematical model to estimate the benefits of screening younger women for breast cancer. *Cancer Detect Prev.* 1981; 4:595–601. [PubMed: 7349826]
30. Cronin KA, Mariotto AB, Clarke LD, Feuer EJ. Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality. *J Natl Cancer Inst Monogr.* 2006:26–29. [PubMed: 17032891]
31. Cronin KA, Yu B, Krapcho M, Miglioretti DL, Fay MP, Izmirlian G, Ballard-Barbash R, Geller BM, Feuer EJ. Modeling the dissemination of mammography in the United States. *Cancer Causes Control.* 2005; 16:701–712. [PubMed: 16049809]
32. Early Breast Cancer Trialists' Collaborative Group. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. *Lancet.* 2012; 379:432–444. DOI: 10.1016/S0140-6736(11)61625-5 [PubMed: 22152853]
33. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. *Med Decis Making.* 2006; 26:391–400. DOI: 10.1177/0272989X06290497 [PubMed: 16855127]
34. Mariotto AB, Feuer EJ, Harlan LC, Abrams J. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. *J Natl Cancer Inst Monogr.* 2006:7–15. [PubMed: 17032888]
35. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. *J Natl Cancer Inst.* 2006; 98:774–782. [PubMed: 16757702]
36. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML. Cost of care for elderly cancer patients in the United States. *J Natl Cancer Inst.* 2008; 100:630–641. DOI: 10.1093/jnci/djn103 [PubMed: 18445825]
37. Mandelblatt J, Near A, Miglioretti DL, Munoz D, Sprague B, Trentham Dietz A, Gangnon R, Kurian A, Weedon-Fekjaer H, Cronin K, Plevritis SK. Common model inputs in collaborative breast cancer modeling. *Med Decis Making.* (in press).
38. Gangnon RE, Stout NK, Alagoz O, Hampton JM, Sprague BL, Trentham Dietz A. Contribution of breast cancer to overall mortality for U. S. women. *Med Decis Making.* (in press).
39. Munoz D, Plevritis S. Estimating breast cancer progression features and survival by molecular subtype in the absence of screening and treatment. *Med Decis Making.* (in press).
40. Cronin KA, Feuer EJ, Clarke LD, Plevritis SK. Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis. *J Natl Cancer Inst Monogr.* 2006:112–121. [PubMed: 17032901]
41. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. 2015
42. Rosenberg MA. The impact of mammography and adjuvant therapy on US breast cancer mortality (1975-2000): collective results from the Cancer Intervention and Surveillance Modeling Network. Competing risks to breast cancer mortality. *J Natl Cancer Inst Monogr.* 2006; 36:15–19.
43. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin.* 2017; 67:7–30. DOI: 10.3322/caac.21387 [PubMed: 28055103]
44. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, de Haes JC, Collette HJ, Hendriks JH, van der Maas PJ. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life

considerations and the possible impact of uncertain factors. *Int J Cancer*. 1991; 49:531–537. [PubMed: 1917154]

45. Grann VR, Patel PR, Jacobson JS, Warner E, Heitjan DF, Ashby-Thompson M, Hershman DL, Neugut AI. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. *Breast Cancer Res Treat*. 2011; 125:837–847. DOI: 10.1007/s10549-010-1043-4 [PubMed: 20644999]
46. Roberts A, Habibi M, Frick KD. Cost-effectiveness of contralateral prophylactic mastectomy for prevention of contralateral breast cancer. *Ann Surg Oncol*. 2014; 21:2209–2217. DOI: 10.1245/s10434-014-3588-7 [PubMed: 24633665]
47. Trentham-Dietz A, Newcomb PA, Nichols HB, Hampton JM. Breast cancer risk factors and second primary malignancies among women with breast cancer. *Breast Cancer Res Treat*. 2007; 105:195–207. [PubMed: 17186360]
48. Bruening W, Fontanarosa J, Tipton K, Treadwell JR, Launders J, Schoelles K. Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions. *Ann Intern Med*. 2010; 152:238–246. DOI: 10.7326/0003-4819-152-1-201001050-00190 [PubMed: 20008742]
49. Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JM, Brookes C, Roberts T, Pirrie S, Gaunt C, Young J, Billingham L, Dodwell D, Hanby A, Pinder SE, Evans A, Reed M, Jenkins V, Matthews L, Wilcox M, Fairbrother P, Bowden S, Rea D. Addressing overtreatment of screen detected DCIS; the LORIS trial. *Eur J Cancer*. 2015; 51:2296–2303. DOI: 10.1016/j.ejca.2015.07.017 [PubMed: 26296293]

Figure 1.

Schema representing breast cancer natural history, detection, and treatment as represented in the simulation model: (A) in the absence of a DCIS prognostic test, and (B) in the presence of a perfect DCIS prognostic test. If the DCIS prognostic test is positive, indicating the DCIS is non-progressive, then the woman receives no treatment and eventually dies from a cause other than breast cancer. If the DCIS prognostic test is negative, the DCIS is progressive, the woman receives breast cancer treatment, and survival depends on the whether the cancer is cured (determined stochastically) and the efficacy of treatment. See

Table 1 for the description of the implementation of the DCIS prognostic test and cancer detection in the simulation model.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 2. Reduction in the number of DCIS cases treated after diagnosis according to the sensitivity and specificity of the hypothetical DCIS prognostic test. Positive DCIS prognostic test indicates non-progressive disease, and a negative DCIS tests indicates progressive disease.

Table 1

Values for costs and quality of life decrements used in the simulation model

Service	Costs[*]
Digital screening mammography (all women without breast cancer)	\$134.98
DCIS prognostic test (all cases diagnosed with DCIS)	\$3,419.42
Breast cancer treatment based on stage at diagnosis and phase of care (duration)	
DCIS and localized invasive	
Initial phase (1 y)	\$14,056
Interim (per year for 10 y)	\$1,717
Terminal (1 y)	\$38,046
Regional invasive	
Initial phase (1 y)	\$26,575
Interim (per year for 10 y)	\$1,717
Terminal (1 y)	\$45,034
Distant invasive	
Initial phase (1 y)	\$41,044
Interim (per year for 10 y)	\$1,717
Terminal (1 y)	\$63,165
Stage of disease at diagnosis (duration)	Utility for Treatment[†]
DCIS and localized invasive (2 y)	0.9
Regional invasive (2 y)	0.75
Distant invasive (until death)	0.6

Abbreviation: DCIS, ductal carcinoma in situ; SEER, Surveillance Epidemiology and End Results

^{*}Costs based on Yabroff [36], Stout [19], and Medicare reimbursement converted to 2015 dollars[†]Disutilities based on Stout [19, 35]. Sensitivity analysis used a utility of 0.8 for DCIS and localized invasive breast cancer treatment, keeping the same values for regional (0.75) and distant breast cancer treatment.

Table 2

Outcomes comparing scenarios with and without a perfect DCIS prognostic test

Measure	No Test	Perfect Prognostic Test for Non-progressive DCIS	Difference (%)
Number of prognostic tests			
Total per 100,000 women	0	2,844	2,844 (100%)
Positive tests per 100,000 women	0	1,696	1,696 (100%)
Number of treated DCIS cases per 100,000 women	2,844	1,148	-1,696 (-59.7%)
Percent of DCIS cases that died of breast cancer	3.0%	3.0%	0
Life-years per DCIS case *	7.598	7.598	0
QALYs per DCIS case after diagnosis *	5.879	5.923	0.044 (0.7%)
Costs per DCIS case *			
Prognostic test	0	\$1,598	\$1,598 (100%)
Surveillance mammography for DCIS test-positive cases	0	\$705	\$705 (100%)
Breast cancer surveillance and treatment for test-negative cases	\$13,321	\$5,701	-\$7,620 (-57.2%)
Total costs per DCIS case	\$13,321	\$8,005	-\$5,316 (-39.9%)
Sensitivity Analysis: Increased quality of life decrement for DCIS treatment †			
QALYs per DCIS case after diagnosis *	5.806	5.894	0.088 (1.5%)
Sensitivity Analysis: Greater percentage of non-progressive tumors ‡			
Number of treated DCIS cases per 100,000 women	3,439	1,125	-2,314 (-67%)
QALYs per DCIS case after diagnosis *	5.932	5.982	0.050 (0.8%)
Costs per DCIS case *	\$13,271	\$7,044	-\$6,227 (-47%)
Sensitivity Analysis: Smaller percentage of non-progressive tumors ‡			
Number of treated DCIS cases per 100,000 women	2,176	1,165	-1,011 (-46%)
QALYs per DCIS case after diagnosis *	5.780	5.814	0.034 (0.6%)
Costs per DCIS case *	\$13,380	\$9,603	-\$3,777 (-28%)

* Life years, QALYs, and costs are discounted at 3% per year. Outcomes averaged across all DCIS cases regardless of whether they received treatment.

† Increased disutility from 0.1 (primary analysis) to 0.2 for 2 years.

‡ Varied the percent of non-progressive tumors from 0.42 in primary analysis (set through model calibration) to 0.3 and 0.5 in secondary analyses.

Table 3

Sensitivity analyses of outcomes based on a DCIS prognostic test with a range of test sensitivity and specificity settings

Modeling Settings for the DCIS Prognostic Test*		Outcomes		
Test Sensitivity, %	Test Specificity, %	Percent of DCIS Cases that Die of Breast Cancer	QALYs per DCIS case[†]	Total Costs per DCIS Case[‡]
100 [‡]	100 [‡]	3.0%	5.923	\$8,005
95	100	3.0%	5.921	\$8,334
90	100	3.0%	5.919	\$8,679
80	100	3.0%	5.915	\$9,357
70	100	3.0%	5.910	\$10,053
60	100	3.0%	5.906	\$10,767
50	100	3.0%	5.901	\$11,452
40	100	3.0%	5.897	\$12,126
30	100	3.0%	5.893	\$12,833
20	100	3.0%	5.888	\$13,521
100	95	3.1%	5.919	\$8,043
100	90	3.2%	5.915	\$8,085
100	85	3.2%	5.910	\$8,121
100	80	3.3%	5.904	\$8,163
100	75	3.3%	5.900	\$8,201
75	95	3.1%	5.909	\$9,754
75	90	3.2%	5.904	\$9,796
75	85	3.2%	5.899	\$9,832
75	80	3.3%	5.893	\$9,874
75	75	3.3%	5.889	\$9,912
50	95	3.1%	5.898	\$11,490
50	90	3.2%	5.893	\$11,532
50	85	3.2%	5.888	\$10,925
50	80	3.2%	5.888	\$11,568
50	75	3.3%	5.882	\$11,610
50	70	3.4%	5.873	\$11,688

* Sensitivity defined as the ability of the test to correctly identify non-progressive disease. Specificity defined as the ability of the test to correctly identify progressive disease.

[†] Discounted at 3% per year.

[‡] Perfect test.